Select clinical recommendations for military medical practitioners conducting humanitarian and civic assistance activities

Military Medicine

Volumn 175, Issue 9, 2010, Pages 647-654

  Hollon, Justin R ^a   Hickey, Patrick W ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTRUISM; ARTICLE; DISASTER PLANNING; FILARIASIS; GOVERNMENT; HEALTH; HELMINTHIASIS; HUMAN; INTERNATIONAL COOPERATION; ORGANIZATION; PEDICULOSIS; PRACTICE GUIDELINE; RESPIRATORY TRACT INFECTION; SCHISTOSOMIASIS; SOLDIER; UNITED STATES; WAR;

AFGHAN CAMPAIGN 2001-; ALTRUISM; DISASTER PLANNING; FILARIASIS; HELMINTHIASIS; HUMANS; INTERNATIONAL COOPERATION; LICE INFESTATIONS; MEDICAL MISSIONS, OFFICIAL; MILITARY PERSONNEL; ORGANIZATIONAL OBJECTIVES; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY TRACT INFECTIONS; SCHISTOSOMIASIS; UNITED STATES; UNITED STATES GOVERNMENT AGENCIES; WORLD HEALTH;

EID: 77956488872     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED-D-10-00005     Document Type: Article

References (67)

1. Department of Defense: Directive 3000.05: Military support for stability, security, transition, and reconstruction (SSTR) operations. Washington, DC, DOD, 2005.
2. Department of the Army: FM 3-24: Counterinsurgency. Washington, DC, DOD, 2006.
3. Department of Defense: Instruction number 2205.02: Humanitarian and civic assistance (HCA) activities. Washington, DC, DOD, 2008.
4. Zajtchuk J: Military medicine in humanitarian missions. In: Military Medical Ethics, Vol 2. Edited by Beam T, Sparacino LR. Washington, DC, Borden Press, 2003.
5. Department of Defense: Joint Publication 3-29: Foreign humanitarian assistance. Washington, DC, DOD, 2009.
6. Ebling L: The DOD humanitarian and civic assistance program: Concepts, trends, medical challenges. Maxwell Air Force Base, AL; Air Command and Staff College, 1997. Available at http://www.au.af.mil/au/awc/awcgate/acsc/97-0377a. pdf; accessed July 20, 2009.
7. Nickle JR: The role of health services support in the theater security cooperation plan: Do we have it right? Newport, Naval War College, 2004. Available at http://handle.dtic.mil/100.2/ADA426005; accessed July 20, 2009.
8. Ritchie EC, Mott RL: Military humanitarian assistance: The pitfalls and promise of good intentions. In: Military Medical Ethics, Vol 2. Edited by Beam T, Sparacino LR. Washington, DC, Borden Press, 2003.
9. Weisser RJ Jr: The maturing of MEDRETEs. Mil Med 1993; 158 (8): 573-5.
10. Chaffi n J, Ott NW, Amador WE: Public health model for dental specialty MEDRETE. Mil Med 2003; 168 (11): 885-9.
11. Lougee D: Can we build a better medical civic assistance program? Making the most of medical humanitarian civic assistance funding. DISAM J 2007; 29 (1): 69-73.
12. World Health Organization: IMCI chart booklet: standard. Geneva, WHO, 2008. Available at http://www.who.int/child-adolescent-health/documents/IMCI- chartbooklet/en/index.html; accessed August 11, 2009.
13. International Pharmaceutical Federation (FIP): MEPS Pictogram Project. International Pharmaceutical Federation. The Hague, The Netherlands, 2009. Available at http://www.fip.nl/www/?page=pp-sect-maepsm-pictogram; accessed July 20, 2009.
14. Pharmacopeia US: USP Pictograms. Rockville, MD, 1997. Available at http://www.usp.org/audiences/consumers/pictograms/; accessed July 20, 2009.
15. Russell FMSF, Curtis N, Mulholland K: Evidence on the use of paracetamol in febrile children. Bull World Health Organ 2003; 81: 367- 72.
16. El-Radhi AS: Why is the evidence not affecting the practice of fever management? Arch Dis Child 2008; 93 (11): 918-20.
17. Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures: American Academy of Pediatrics: Febrile seizures: clinical practice guideline for the long-term management of the child with simple febrile seizures. Pediatrics 2008; 121 (6): 1281- 6.
18. Brandts CH, Ndjave M, Graninger W, Kremsner PG: Effect of paracetamol on parasite clearance time in Plasmodium falciparum malaria. Lancet 1997; 350 (9079): 704-9.
19. Doran TF, De Angelis C, Baumgardner RA, Mellits ED: Acetaminophen: more harm than good for chickenpox? J Pediatr 1989; 114 (6): 1045-8.
20. World Health Organization: The interagency emergency health kit. Geneva, WHO, 2006. Available at http://www.who.int/hac/techguidance/tools/IEHK2006.pdf; accessed August 11, 2009.
21. World Health Organization: Guidelines for the Treatment of Malaria, Ed 2. Geneva, WHO, 2010. Available at http://whqlibdoc.who.int/publications/2010/ 9789241547925-eng.pdf; accessed April 14, 2010.
22. Monto AS: The disappearance of Reye's syndrome-a public health triumph. N Engl J Med 1999; 340 (18): 1423-4.
23. Perrott DA, Piira T, Goodenough B, Champion GD: Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. Arch Pediatr Adolesc Med 2004; 158 (6): 521-6.
24. Clark E, Plint AC, Correll R, Gaboury I, Passi B: A randomized, controlled trial of acetaminophen, ibuprofen, and codeine for acute pain relief in children with musculoskeletal trauma. Pediatrics 2007; 119 (3): 460-7.
25. Cooper SA, Schachtel BP, Goldman E, Gelb S, Cohn P: Ibuprofen and acetaminophen in the relief of acute pain: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol 1989; 29 (11): 1026-30.
26. Lesko SM, Mitchell AA: The safety of acetaminophen and ibuprofen among children younger than two years old. Pediatrics 1999; 104 (4): e39.
27. Schaefer MK, Shehab N, Cohen AL, Budnitz DS: Adverse events from cough and cold medications in children. Pediatrics 2008; 121 (4): 783-7.
28. U.S. Food and Drug Administration: FDA news: advisory committees recommend against cough and cold medications in children under 6. Silver Spring, MD, FDA, 2007. Available at http://www.fdanews.com/newsletter/article?issueId= 10894&articleId=100077; accessed August 24, 2009.
29. World Health Organization: Cough and cold remedies for the treatment of acute respiratory infections in young children. Geneva, WHO, 2001. Available at http://www.who.isourcent/child-adolescent-health/documents/fch-cah-01-02/en/ index.html; accessed June 13, 2009.
30. Schroeder K, Fahey T: Systematic review of randomised controlled trials of over the counter cough medicines for acute cough in adults. BMJ 2002; 324 (7333): 329-31. (Pubitemid 34142752)
31. Smith MB, Feldman W: Over-the-counter cold medications. A critical review of clinical trials between 1950 and 1991. JAMA 1993; 269 (17): 2258-63.
32. Centers for Disease Control and Prevention: Infant deaths associated with cough and cold medications-two states, 2005. MMWR Morb Mortal Wkly Rep 2007; 56 (1): 1-4.
33. Gunn VL, Taha SH, Liebelt EL, Serwint JR: Toxicity of over-the-counter cough and cold medications. Pediatrics 2001; 108 (3): E52.
34. Rimsza ME, Newberry S: Unexpected infant deaths associated with use of cough and cold medications. Pediatrics 2008; 122 (2): e318-22.
35. World Health Organization: Preventive chemotherapy in human helminthiasis: coordinated use of anthelmintic drugs in control interventions. A manual for health professionals and programme managers. Geneva, WHO, 2006. Available at http://whqlibdoc.who.int/publications/2006/9241547103-eng.pdf; accessed June 14, 2009.
36. Keiser J, Utzinger J: Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008; 299 (16): 1937-48.
37. World Health Organization: Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO expert commitee. World Health Organization Technical Report Series 912. Geneva, WHO, 2002. Available at http://whqlibdoc.who.int/trs/WHO-TRS-912.pdf accessed June 14, 2009.
38. World Health Organization: The evidence is in: Deworming helps meet the Millenium Development Goals. Geneva, WHO, 2005. Available at http://whqlibdoc.who.int/hq/2005/WHO-CDS-CPE-PVC-2005.12.pdf; accessed June 14, 2009.
39. Bethony J, Brooker S, Albonico M, et al: Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006; 367 (9521): 1521-32.
40. Huppatz C, Durrheim DN. Control of neglected tropical diseases. N Engl J Med 2007; 357 (23): 2407; author reply, 2408.
41. World Health Organization: WHO Model List of Essential Medicines, Ed 15. Geneva, WHO, 2007. Available at http://www.who.int/medicines/publications/08- ENGLISH-indexFINAL-EML15.pdf; accessed June 13, 2009.
42. World Health Organization: Report of the WHO informal consultation on the use of praziquantel during pregnancy/lactation and albendazole/mebendazole in children under 24 months. Geneva, WHO, 2002. Available at http://www.who.int/ wormcontrol/documents/en/pvc-20024full.pdf; accessed June 13, 2009.
43. World Health Organization: Controlling disease due to helminth infections. Edited by Crompton DWT, Montresor A, Nesheim MC, Savioli L. Geneva, WHO, 2003. Available at http://www.who.int/wormcontrol/documents/en/ Controlling%20Helminths.pdf; accessed June 14, 2009.
44. Stephenson L, Latham M, Adams E, Kinoti S, Pertet A: Physical fi tness, growth and appetite of Kenyan school boys with hookworm, Trichuris trichiura and Ascaris lumbricoides infections are improved four months after a single dose of albendazole. J Nutr 1993; 123 (6): 1036-46.
45. Belizario VY, Amarillo ME, de Leon WU, de los Reyes AE, Bugayong MG, Macatangay BJ: A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp. Bull World Health Organ 2003; 81 (1): 35-42.
46. World Health Organization: Lymphatic fi lariasis: Fact sheet no. 102. Geneva, WHO, 2000. Available at http://www.who.int/mediacentre/factsheets/fs102/ en/; accessed June 14, 2009.
47. Shenoy RK, Suma TK, Kumaraswami V, Rahmah N, Dhananjayan G, Padma S: Antifi larial drugs, in the doses employed in mass drug administrations by the Global Programme to Eliminate Lymphatic Filariasis, reverse lymphatic pathology in children with Brugia malayi infection. Ann Trop Med Parasitol 2009; 103 (3): 235-47.
48. Reddy M, Gill SS, Kalkar SR, Wu W, Anderson PJ, Rochon PA: Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA 2007; 298 (16): 1911-24.
49. Francis H, Awadzi K, Ottesen EA: The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am J Trop Med Hyg 1985; 34 (3): 529-36.
50. Beach MJ, Streit TG, Addiss DG, Prospere R, Roberts JM, Lammie PJ: Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am J Trop Med Hyg 1999; 60 (3): 479-86.
51. Montresor A, Odermatt P, Muth S, et al: The WHO dose pole for the administration of praziquantel is also accurate in non-African populations. Trans R Soc Trop Med Hyg 2005; 99 (1): 78-81.
52. Strandgaard H, Johansen MV, Montresor A, Ornbjerg N: Field testing of the WHO dose pole for administration of praziquantel in the treatment of opisthorchiasis in Lao PDR. Trans R Soc Trop Med Hyg 2007; 101 (11): 1120-3.
53. Mohammed KA, Haji HJ, Gabrielli AF, et al: Triple co-administration of ivermectin, albendazole and praziquantel in zanzibar: a safety study. PLoS Negl Trop Dis 2008; 2 (1): e171.
54. Brooks PA, Grace RF: Ivermectin is better than benzyl benzoate for childhood scabies in developing countries. J Paediatr Child Health 2002; 38 (4): 401-4.
55. Strong M, Johnstone PW: Interventions for treating scabies. Cochrane Database Syst Rev 2007; (3): CD000320.
56. Heukelbach J, Winter B, Wilcke T, et al: Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected population. Bull World Health Organ 2004; 82 (8): 563-71.
57. Frankowski BL: American Academy of Pediatrics guidelines for the prevention and treatment of head lice infestation. Am J Manag Care 2004; 10 (9, Suppl): S269-72.
58. Chosidow O, Giraudeau B, Cottrell J, et al: Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med 2010; 362 (10): 896-905.
59. Hu S, Bigby M: Treating scabies: results from an updated Cochrane review. Arch Dermatol 2008; 144 (12): 1638-40, discussion 40-1.
60. U.S. Food and Drug Administration: Public health advisory: safety of topical lindane products for the treatment of scabies and lice. Silver Spring, MD, FDA, 2003. Available at http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm110845.htm; accessed August 24, 2009.
61. Fischer TF: Lindane toxicity in a 24-year-old woman. Ann Emerg Med 1994; 24 (5): 972-4.
62. Lebwohl M, Clark L, Levitt J: Therapy for head lice based on life cycle, resistance, and safety considerations. Pediatrics 2007; 119 (5): 965-74.
63. Pollack RJ, Kiszewski A, Armstrong P, et al: Differential permethrin susceptibility of head lice sampled in the United States and Borneo. Arch Pediatr Adolesc Med 1999; 153 (9): 969-73.
64. Burgess IF, Brown CM, Peock S, Kaufman J: Head lice resistant to pyrethroid insecticides in Britain. BMJ 1995; 311 (7007): 752.
65. Burkhart CG, Burkhart CN: Head lice therapies revisited. Dermatol Online J 2006; 12 (6): 3.
66. Frankowski BL, Weiner LB: Head lice. Pediatrics 2002; 110 (3): 638-43.
67. Glaziou P, Nyguyen LN, Moulia-Pelat JP, Cartel JL, Martin PM: Efficacy of ivermectin for the treatment of head lice (Pediculosis capitis). Trop Med Parasitol 1994; 45 (3): 253-4.